Drug intelligence / Profile preview

bicalutamide + ribociclib

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Bicalutamide + ribociclib is a combination therapy being investigated for the treatment of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC). This combination pairs bicalutamide, a nonsteroidal anti-androgen that blocks androgen receptors, with ribociclib, a CDK4/6 inhibitor. The rationale behind this combination is that CDK4/6 inhibition may enhance the activity of androgen inhibitors, as seen in previous prostate cancer cell lines. Preliminary studies suggest the combination has tolerable toxicity profiles and may provide improved clinical benefit compared to either agent alone.

Targets

CDK6 (Cyclin-dependent kinase 6)AR (Adrenergic receptors)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on bicalutamide + ribociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bicalutamide + ribociclib.

Explore the full profile